The Power List 2020 – Small Molecules
Chief Technology Officer at Nanoform
Niklas Sandler has extensive experience in both industry and academia, particularly within the fields of pharmaceutical product development and material science. Alongside his role as chief technology officer at Nanoform, he is also a professor at Åbo Akademi University with over 100 published papers in several pharmaceutical journals.
When asked if small molecules were still a big for pharma, he responded:
“Small molecules are still a crucial part of development pipelines and cover many therapeutic areas. New technologies, including nanotechnology, will boost the potential of these molecules to create future therapies. Also, old treatments will benefit from technologies that improve drug performance and provide life cycle extension opportunities for existing drugs.”